Conditions: Osteoporosis
Keywords: osteoporosis postmenopausal denosumab teriparatide Forteo® DXA Bone Mineral Density pQCT
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 94
Healthy volunteers: no

Brief summary:
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: denosumab intervention 2: teriparatide
Intervention descriptions: intervention 1: denosumab: 60 mg SC every 6 months intervention 2: teriparatide: 20 mcg SC QD

Protocol document: